Phase 1/2 Study of UI-102 in Selected Advanced Cancers

Biological Therapy in Treating Patients With Advanced Cancer

NCT00005956 ·Status: COMPLETED ·Phase: NA

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

NCT01783431 ·Status: TERMINATED ·Phase: PHASE1

Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03735589 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

NCT04270864 ·Status: TERMINATED ·Phase: PHASE1

Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers

NCT03568058 ·Status: COMPLETED ·Phase: PHASE1

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

NCT04338659 ·Status: COMPLETED ·Phase: PHASE1

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

NCT04815356 ·Status: RECRUITING ·Phase: PHASE1

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

NCT05334329 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Universal Immunization to Fortify Immunotherapy Efficacy and Response

NCT07597070 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

NCT03970382 ·Status: SUSPENDED ·Phase: PHASE1

Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT01976520 ·Status: UNKNOWN ·Phase: PHASE1

First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients

NCT05964361 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma

NCT00683670 ·Status: COMPLETED ·Phase: PHASE1

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

NCT00066651 ·Status: COMPLETED ·Phase: PHASE1

A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors

NCT03295942 ·Status: TERMINATED ·Phase: PHASE1

A Study of Atezolizumab in Advanced Solid Tumors

NCT02458638 ·Status: COMPLETED ·Phase: PHASE2

An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.

NCT07420010 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1

Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors

NCT07259889 ·Status: RECRUITING ·Phase: PHASE1

Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine

NCT00176761 ·Status: TERMINATED ·Phase: PHASE2

Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

NCT02675439 ·Status: TERMINATED ·Phase: PHASE1

NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts

NCT04960059 ·Status: COMPLETED

Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG

NCT03695757 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Preoperative Intratumor Dendritic Cells Injection Immunotherapy for Patients With Pancreatic Cancer

NCT00795977 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults

NCT02496520 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies

NCT06528249 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1